The story in detail
Researchers tested whether semaglutide could influence ageing-related processes in older female mice. Treatment began at 20 months, with physiological and molecular assessments after three months and lifespan follow-up during continued treatment. Some experiments directly compared the drug with matched calorie restriction. Shared benefits and differences between the interventions suggested questions beyond reduced food intake alone.
The central boundary is that these were female mice, not people. Longer mouse lifespan does not establish human longevity benefits, and the same response cannot be assumed in males or other conditions. The study addresses a basic research question distinct from established clinical uses of the medicine. It should not be presented as evidence for healthy people to start treatment to slow ageing.
Updated: 20 October 2026 · Study date: 2026-09-02
What was found?
In experiments starting with 20-month-old female mice, semaglutide improved some movement and cognitive measures. With treatment continued until death, median lifespan was 834 days versus 742 in controls.
What does it mean?
The work explores connections between metabolic medicines and ageing biology. Comparisons with calorie restriction suggested that the two approaches may not have identical effects.
Limitations
These were older female mice, not humans. The results cannot determine human doses or lifespan gains and are not clinical evidence for using semaglutide to delay ageing.
Sources and review scope
English adaptation of the reviewed Turkish edition. The translation preserves its study population, uncertainty and limitations. It is not an independent new study review. Translation checked: 20 October 2026.
Editorial expansion: 21.10.2026
Keep this story
Feedback to the editor
Only the editor can read this; it is not a public comment. Do not include personal health information.
Sign in to send feedback